文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌的州级膀胱内治疗率在卡介苗药物短缺期间的变化

Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage.
PubMed 文献 · Urology · 2023-03-25

该研究利用5%的医疗保险受益人随机样本,分析了2010至2017年间7971例66岁及以上膀胱癌患者(短缺前2648例,短缺期间5323例)在诊断后1年内接受膀胱内治疗的情况。结果显示,短缺期间卡介苗使用率下降5.9%(95% CI -8.2%至-3.7%),完成全程诱导疗程的比例从31.0%降至27.6%(P=0.002),且84%的报告州(16/19)卡介苗使用率下降5%至36%。

要点

  • 卡介苗短缺期间膀胱内卡介苗使用率下降5.9%(95% CI -8.2%至-3.7%)。
  • 完成卡介苗全程诱导疗程比例从31.0%降至27.6%(P=0.002)。
  • 84%的报告州(16/19)卡介苗使用率较短缺前下降5%至36%。

核心结论

  • 卡介苗药物短缺期间,符合条件的膀胱癌患者接受金标准膀胱内卡介苗治疗的可能性降低,且美国各州治疗模式存在较大差异。

研究设计与样本

  • 使用5%的医疗保险受益人随机样本,识别2010至2017年间诊断后1年内接受膀胱内治疗的7971例66岁及以上膀胱癌患者,其中卡介苗短缺前2648例,短缺期间5323例。
  • 卡介苗短缺期定义为2012年7月及以后持续至今。
  • 全程诱导治疗定义为60天内接受6次治疗中的至少5次,药物包括卡介苗、丝裂霉素C、吉西他滨或其他膀胱内药物。
  • 比较每个时期至少报告50例患者的美国各州的州级卡介苗使用情况;自变量包括索引日期年份、年龄、性别、种族、城乡居住地和居住地区。

主要发现

  • 短缺期间卡介苗使用率下降5.9%(95% CI -8.2%至-3.7%)。
  • 完成卡介苗全程诱导疗程的患者比例从短缺前的31.0%降至短缺期间的27.6%(P=0.002)。
  • 84%的报告州(19个州中的16个)卡介苗使用率较短缺前下降,降幅在5%至36%之间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To measure the changes in treatment patterns for non-muscle invasive bladder cancer before and during the Bacillus Calmette-Guerin (BCG) drug shortage. MATERIALS AND METHODS: We used a 5% random sample of Medicare beneficiaries and identified 7971 bladder cancer patients (2648 pre-BCG shortage and 5323 during the shortage) ≥66 years of age who received intravesical treatment within 1 year of diagnosis between 2010 and 2017. The BCG shortage period was defined from July 2012 ongoing. Full induction treatment with BCG, mitomycin C, gemcitabine, or other intravesical agents was defined as receiving ≥5 of 6 treatments within 60 days. State-level BCG use before and during the drug shortage was compared in US states reporting at least 50 patients in each period. Independent variables included year of index date, age, sex, race, rurality, and region of residence. RESULTS: BCG utilization rates decreased 5.9% in the shortage period (95% CI (-8.2%)-(-3.7%)). The proportion of patients that completed a full induction course of BCG decreased from 31.0% in the pre-shortage period to 27.6% in the shortage period (P = .002). 84% of reporting states (16 of 19) had decreased BCG utilization ranging between 5% and 36% compared to pre-shortage rates. CONCLUSION: During the BCG drug shortage, eligible bladder cancer patients were less likely to receive gold standard intravesical BCG with a large variation in treatment patterns between US states.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chun B, He M, Jones C, et al. Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage. Urology. 2023. PMID: 36972766. doi:10.1016/j.urology.2023.02.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。